Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
2026-10-12 18:40
•Brendan Coffey •The Motley Fool
•••••• •••• Axe Cap view
Abbott vs Intuitive Surgical: Healthcare Stocks for 2026
Abbott’s steady valuation and cash flow make it a better bet than Intuitive Surgical’s premium growth story.
Abbott Laboratories (ABT) offers a grounded healthcare play with its diversified portfolio spanning diagnostics, nutrition, and medical devices. Trading at a modest 18x forward P/E and yielding nearly 2.5% in dividends, Abbott brings solid cash flow and less risk than the flashy but pricey Intuitive Surgical. Intuitive’s 39x multiple prices in aggressive growth from robotic surgery dominance, but competition from Medtronic and Johnson & Johnson is heating up, which could curb its expansion. For South African investors, this means exposure through global healthcare that balances growth and income without chasing a stretched valuation. Abbott’s recent move into cancer screening via Exact Sciences adds a long-term tailwind, while Intuitive’s premium limits upside if markets turn. Watch USD/ZAR closely since dollar strength can impact offshore returns. The view could be wrong if Intuitive’s innovation vaults past competitors faster than expected, justifying its rich price. this is just our opinion and not financial advice
Buy Abbott Laboratories for steady growth and income, while watching Intuitive Surgical for selective entry if valuation normalises.
- ABT
- USD/ZAR
- Intuitive faces growing competition
- USD/ZAR volatility impacting offshore returns
6/10
Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.
Our take is based on reporting first published by The Motley Fool.